pancreatic cancer
Conditions
Interventions
experimental group:gemcitabine combined with nab-paclitaxel
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) patients with locally advanced or metastatic pancreatic cancer confirmed by pathology; 2) adenocarcinoma of pancreatic duct confirmed by cytology or histology; 3) have not received any systematic anti-tumor treatment before; 4) aged 18 to 80 years; 5) estimated survival time >=3 months; 6) ECoG PS score 0-1; 7) there is at least one measurable tumor focus: on spiral CT, the long diameter >=10 mm, the short diameter >=15 mm; on general CT or physical examination, the maximum diameter must be >=20 mm; 8) patients participate voluntarily and sign informed consent.
Exclusion criteria
Exclusion criteria: 1) those who are known to be seriously allergic to gemcitabine and albumin Paclitaxel; 2) patients with obvious coagulation mechanism disorder, active bleeding and bleeding tendency; 3) have other malignant tumor history within 5 years (except for skin basal cell carcinoma and cervical carcinoma in situ which are fully treated); 4) interstitial pneumonia or pulmonary fibrosis; 5) uncontrollable pleural effusion or ascites; 6) patients with serious uncontrolled internal diseases, acute infection and recent history of myocardial infarction (within 3 months); 7) pregnancy or lactation, as well as childbearing age patients who refuse to take appropriate contraceptive measures in the process of this trial; 8) patients not suitable for the study were judged by the researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| OS; | — |
Secondary
| Measure | Time frame |
|---|---|
| PFS;ORR;AE;QOL; | — |
Countries
China
Contacts
Public ContactDan Cao
West China Hospital, Sichuan University
Outcome results
None listed